HARVARD BIOSCIENCE INC 8-K

What Happened

• Harvard Bioscience, Inc. announced on January 19, 2026 that its Board of Directors approved an amendment to the company’s Amended and Restated By‑laws. The amendment reduces the quorum requirement for stockholder meetings from a majority to one‑third (1/3) of the shares of capital stock entitled to vote and became effective upon the Board’s adoption.

Key Details

• Board approval date: January 19, 2026.
• New quorum threshold: one‑third (1/3) of shares entitled to vote (previously a majority).
• The amendment is filed as Exhibit 3.1 to the Current Report on Form 8‑K.
• The change is to the company’s Amended and Restated By‑laws (Delaware corporation).

Why It Matters

• A lower quorum makes it easier for the company to hold valid stockholder meetings and transact business when fewer voting shares are present or represented, which can affect how and when shareholder votes occur.
• Investors concerned about corporate governance or shareholder rights may want to review the filed by‑laws amendment (Exhibit 3.1) and monitor any future meeting notices or proposals for additional context.